AllPennyStocks.com G Q2 Earnings Beat Estimates on ATS Growth, Outlook Raised
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

G Q2 Earnings Beat Estimates on ATS Growth, Outlook Raised

Genpact Limited G reported better-than-expected second-quarter 2026 results. Adjusted earnings of $1 per share, up 13.6% year over year and above the consensus mark of 97 cents by 3.1%. Net revenues increased 7.1% to $1.34 billion and beat estimates by roughly 1%.

Performance was driven by Advanced Technology Solutions, or ATS, which grew 24.1% year over year. Gross margin expanded to 36.5%, while non-FTE revenue surpassed 50% of total revenues for the first time.

Genpact Limited Price, Consensus and EPS Surprise

Genpact Limited Price, Consensus and EPS Surprise

Genpact Limited price-consensus-eps-surprise-chart | Genpact Limited Quote

G’s Advanced Technology Solutions Accelerate

ATS revenues increased to $363 million from $292.7 million a year ago and represented 27% of total revenues. Growth was broad-based across Data & AI, Digital Technologies, Advisory and Agentic offerings.

Management now expects ATS revenues to grow at least 25% in 2026, up from its previous expectation of at least 20%. The company said demand for agentic and AI-led services continues to accelerate as clients seek to automate more complex enterprise workflows.

Genpact’s Core Business Maintains Growth

Core Business Services revenues rose 1.9% year over year to $980 million and accounted for 73% of revenues. Genpact continued to see demand across Digital Operations, Decision Support Services and Technology Services.

Management expects Core Business Services to grow for the full year despite a deliberate transition away from certain lower-priority work. This portfolio shift is expected to reduce total 2026 revenue growth by nearly 2 percentage points, with the impact concentrated in the second half.

G Expands Margins Amid Higher Investments

Gross profit advanced 8.9% year over year to $490.3 million. Gross margin expanded about 60 basis points to 36.5%, marking the 13th consecutive quarter of year-over-year gross margin improvement.

Adjusted income from operations increased 7.5% to $233.6 million, while the adjusted operating margin improved to 17.4% from 17.3%. Selling, general and administrative expenses were $294.1 million compared with $266.4 million in the prior-year quarter.

Genpact’s Agentic Bookings Gain Momentum

Genpact recorded its largest-ever quarterly bookings and signed six large deals compared with three in the year-ago period. This brought first-half large-deal wins to 12, double the prior-year level. Large deals are defined as contracts worth at least $50 million.

The company expects more than $1 billion in Agentic Solutions total contract value during 2026, roughly five times the 2025 level. More than half of cumulative agentic contract value has come from new clients, highlighting the strategy’s ability to expand Genpact’s addressable market.

G’s Cash Flow Reflects Collection Timing

Cash generated from operations was $72 million compared with $177 million a year ago. Management attributed the decline partly to collection timing and prepayments made in 2025.

Genpact ended June with $517.4 million in cash and cash equivalents. During the quarter, it returned $82 million to shareholders, consisting of roughly $50 million in share repurchases and $32 million in dividends.

Genpact Raises 2026 Earnings Outlook

For the third quarter, Genpact expects revenues of $1.369-$1.382 billion. The midpoint of $1.376 billion is about 0.3% below the Zacks Consensus Estimate of $1.38 billion. Adjusted earnings are projected at $1.04-$1.05 per share, with the midpoint of $1.045 slightly above the consensus estimate of $1.04.

For 2026, Genpact continues to expect reported revenue growth of at least 7%. Using the provided year-ago sales figure of $5.08 billion, this implies revenues of at least $5.44 billion, slightly above the $ 5.43 billion Zacks Consensus Estimate. The company also raised adjusted diluted earnings growth guidance to at least 12%. Its outlook reconciliation indicates adjusted earnings of $4.09 per share, about 1% above the consensus estimate of $4.05. Genpact expects a 36.5% gross margin and a 17.7% adjusted operating margin for the year.

G currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Earnings Snapshots

Trane Technologies TT reported impressive second-quarter 2026 results. TT’s adjusted earnings of $4.31 per share outpaced the consensus mark by 0.9% and rose 11.1% from the year-ago quarter’s actual. TT’s total revenues of $6.35 billion surpassed the consensus mark by 2.9% and increased 6.4% year over year.

Rollins ROL posted unimpressive second-quarter 2026 results. ROL’s adjusted earnings of 32 cents per share missed the Zacks Consensus Estimate by 5.9% but rose 6.7% year over year. Total revenues of $1.08 billion fell short of the consensus estimate by 1.7% but increased 7.9% from the year-ago quarter.

Verisk VRSK reported second-quarter 2026 diluted adjusted earnings of $1.98 per share, beating the Zacks Consensus Estimate of $1.94 by 2.1%. The figure increased 5.3% from the year-ago quarter. Revenues of $806.3 million topped the consensus mark of $802.4 million by 0.5% and rose 4.3% year over year.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Genpact Limited (G): Free Stock Analysis Report
 
Rollins, Inc. (ROL): Free Stock Analysis Report
 
Verisk Analytics, Inc. (VRSK): Free Stock Analysis Report
 
Trane Technologies plc (TT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Other Penny Stock Movers

The Legacy Product Is Shrinking. A New One is Growing 250%
Brazilian Developer Jumps 11% as Court Lifts Injunction
Deep Utah Porphyry Intercept Triggers 57% Rally as Drilling Continues Past 550m


Back to Top